Idera Pharmaceuticals to Present at Upcoming Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced that it will provide an overview of its drug discovery and development programs targeted to Toll-like Receptors and a general corporate update at the following conferences:

  • OneMed Forum NY 2011 on Thursday, June 23, 2011 at 12:15 p.m. ET at The Roosevelt Hotel in New York City
  • BIO Business Forum and International Convention on Thursday, June 30, 2011 at 10:30 a.m. ET at the Walter E. Washington Convention Center in Washington, D.C.

The live audio webcast of the OneMed Forum NY 2011 presentation will be available in the Investor section of the company’s website at www.iderapharma.com. Archived replays will also be available on the company’s site for two weeks following the event. Please log in approximately 10 minutes prior to the presentation to ensure a timely connection.

About Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals develops drug candidates to treat infectious diseases, autoimmune and inflammatory diseases, cancer, and respiratory diseases, and for use as vaccine adjuvants. Our proprietary drug candidates are designed to modulate specific Toll-like Receptors, which are a family of immune system receptors that direct immune system responses. Our pioneering DNA and RNA chemistry expertise enables us to create drug candidates for internal development and generates opportunities for multiple collaborative alliances. For more information, visit www.iderapharma.com.



CONTACT:

Idera Pharmaceuticals, Inc.
Teri Dahlman, 617-679-5519
[email protected]
or
MacDougall Biomedical Communications
Chris Erdman, 781-235-3060
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Genetics  Oncology  Pharmaceutical  General Health

MEDIA:

Logo
 Logo

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.